Planegg/Martinsried – Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that its Annual General Meeting (AGM) approved all resolutions proposed by the Executive Management Board and the Supervisory Board:
* Discharge of the members of the Executive Management Board and Supervisory Board for the financial year 2020;
* Re-election of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as auditor for the financial year 2021;
* Re-elections of Ronald Scott and Dr. Gerd Zettlmeissl to the Supervisory Board;
* The remuneration system of the Executive Management Board.
The Executive Management Board of the Company informed the shareholders about the progress and results of the 2020 fiscal year, and about major events in the first months of 2021, including recruitment of the last patient into the third dose cohort of the Phase I part of the MDG1011 clinical trial, the identification of ten novel tumor-specific antigens which can be targeted by T cell receptors (TCRs), that have been isolated by Medigene’s proprietary discovery process, and the publication of compelling in vivo data on the use of Medigene’s lead T cell receptor candidate TCR-4 combined with its PD1-41BB switch receptor to overcome immunosuppressive solid tumor microenvironments.
Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene: “Medigene’s development projects continued to progress well in 2020 and the early part of 2021. Our ventures targeting solid tumors have achieved impressive preclinical results on multiple projects, including the selection of optimal TCRs, unique new tumor-specific antigens, and functional enhancements for TCR-modified T cells such as the PD1-41BB switch receptor to conquer hostile tumor environments.
Medigene’s frequency of presentations at international conferences, as well as our peer-reviewed publication of work on the MAGE-A4-specific TCR in collaboration with bluebird bio, demonstrate our commitment towards patient-centered innovation. To facilitate our growth in the fight against cancer, we continue to evaluate new partnering opportunities related to our suite of TCR technologies and portfolio of product candidates.”
Medigene’s Executive Management Board and Supervisory Board would like to thank the shareholders of Medigene AG for their continued support in the Company.
The presentation of the AGM and Medigene’s updated corporate presentation can be found at Medigene’s website at https://medigene.com/investors-media/reports-presentations.
— end of press release —
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Planegg/Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to enhance T cell activity against solid cancers in fields of high unmet medical need. Medigene’s pipeline includes pre-clinical as well as clinical programs in development.
Medigene’s strategy is to develop its own therapies towards clinical proof-of-concept. In addition, the Company offers selected partners the opportunity to discover and develop therapies on the basis of its proprietary technology platforms. In return for such partnerships, Medigene expects to receive upfront and milestone payments as well as research and development funding and royalties on future product sales.
For more information, please visit https://medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Dr. Anna Niedl
Phone: +49 89 2000 3333 01
Phone: +44 7483 284 853